News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
260,010 Results
Type
Article (13740)
Company Profile (104)
Press Release (246166)
Section
Business (88233)
Career Advice (485)
Deals (15376)
Drug Delivery (60)
Drug Development (36712)
Employer Resources (54)
FDA (6263)
Job Trends (6242)
News (150450)
Policy (14035)
Tag
Academia (440)
Africa (314)
Alliances (23126)
Alzheimer's disease (328)
Approvals (6246)
Arizona (35)
Artificial intelligence (40)
Asia (19706)
Australia (2534)
Bankruptcy (143)
Best Places to Work (4228)
Biosimilars (32)
Biotechnology (41)
C2C Services and Suppliers (10609)
California (590)
Canada (425)
Cancer (129)
Career advice (417)
Cell therapy (23)
China (64)
Clinical research (30216)
Collaboration (49)
Compensation (23)
Connecticut (24)
COVID-19 (745)
Data (84)
Diabetes (25)
Diagnostics (1204)
Drug pricing (47)
Earnings (31288)
Employer resources (48)
Europe (38549)
Events (36438)
Executive appointments (78)
FDA (6326)
Florida (73)
Funding (36)
Gene therapy (42)
GLP-1 (262)
Government (1258)
Healthcare (3549)
Hotbed/Location (178625)
Illinois (70)
Indiana (57)
Infectious disease (750)
Inflammatory bowel disease (41)
Interviews (60)
IPO (5811)
Job creations (2061)
Job search strategy (385)
Kansas (49)
Layoffs (173)
Legal (3406)
Lung cancer (27)
Manufacturing (43)
Maryland (84)
Massachusetts (521)
Medical device (1252)
Medtech (1254)
Mergers & acquisitions (9503)
Metabolic disorders (99)
Minnesota (37)
Neuroscience (379)
New Jersey (237)
New York (162)
NextGen Class of 2024 (1587)
Non-profit (598)
North Carolina (222)
Northern California (260)
Now hiring (22)
Obesity (60)
Ohio (28)
Opinion (109)
Patents (39)
Pennsylvania (183)
People (28367)
Pharmaceutical (60)
Phase I (7885)
Phase II (12769)
Phase III (11476)
Pipeline (50)
Podcasts (37)
Policy (36)
Postmarket research (1401)
Preclinical (3157)
Press Release (25)
Rare diseases (51)
Real estate (2631)
Regulatory (9718)
Research institute (566)
Resumes & cover letters (60)
South America (498)
Southern California (260)
Startups (1629)
Texas (75)
The Weekly (23)
United States (2598)
Vaccines (97)
Washington State (46)
Weight loss (52)
Date
Today (48)
Last 7 days (218)
Last 30 days (788)
Last 365 days (13508)
2024 (9316)
2023 (14418)
2022 (19707)
2021 (20224)
2020 (19125)
2019 (14970)
2018 (11766)
2017 (13961)
2016 (13165)
2015 (15527)
2014 (12442)
2013 (10608)
2012 (11435)
2011 (11947)
2010 (10909)
260,010 Results for "takeda pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Takeda’s Epilepsy Drug Stumbles in Back-to-Back Phase III Rare Disease Failures
Takeda’s soticlestat, licensed from Ovid Therapeutics, did not significantly reduce seizures in patients with Dravet syndrome and Lennox-Gastaut syndrome, respectively, according to two late-stage readouts on Monday.
June 17, 2024
·
2 min read
·
Tristan Manalac
Drug Development
Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
Ovid Therapeutics Inc., a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by rare epilepsies and brain conditions, reports that Takeda Pharmaceutical Company Limited has announced topline data from its Phase 3 SKYLINE and SKYWAY studies evaluating soticlestat for the treatment of Dravet syndrome and Lennox-Gastaut syndrome.
June 17, 2024
·
12 min read
Business
Takeda Announces New Assignments of Directors - June 26, 2024
Takeda has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting, following the 148th Ordinary Meeting of Shareholders, held in Osaka.
June 26, 2024
·
6 min read
Job Trends
HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that its partner Takeda (TSE:4502/NYSE:TAK) has received notification from the European Commission (“EC”) that it has approved FRUZAQLA®.
June 21, 2024
·
17 min read
Business
JCR Pharmaceuticals and Takeda Pharmaceuticals Announce Discontinuation of Gene Therapy Collaboration
JCR Pharmaceuticals Co., Ltd. announced today that Takeda Pharmaceutical Co., Ltd. (“Takeda”) decided to discontinue their collaboration with JCR to develop gene therapies using adeno-associated viruses (AAV) combined with the JCR J-Brain Cargo ® Technology.
December 21, 2023
·
4 min read
BioCapital
Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda
Ascentage Pharma, a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B, and age-related diseases, announced that the agreed equity investment by Takeda has been closed on June 20, 2024, with all proceeds already received.
June 20, 2024
·
3 min read
Business
Takeda Joins Hot Molecular Glue Market With $1.2B Deal
Riding the growing wave of interest in molecular glue degraders, Takeda has partnered with Chinese biotech Degron Therapeutics to develop novel therapies for oncology, neuroscience and inflammation.
May 23, 2024
·
2 min read
·
Tristan Manalac
Policy
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
Takeda announced that LIVTENCITY® has been approved by the Japanese Ministry of Health, Labour and Welfare for post-transplant cytomegalovirus infection/disease that is refractory to existing anti-CMV therapies
June 24, 2024
·
15 min read
Policy
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
Takeda announced that the EC approved FRUZAQLA as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib.
June 21, 2024
·
18 min read
Drug Development
Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo
Takeda will present positive results from its Phase 2b trial of TAK-861 in narcolepsy type 1 as late-breaking data presentations at SLEEP 2024, the 38th annual meeting of the American Academy of Sleep Medicine and the Sleep Research Society.
June 3, 2024
·
10 min read
1 of 26,001
Next